{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:48:38Z","timestamp":1788580118437,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007188","name":"Uniformed Services University of the Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010201","name":"U.S. Army Medical Research Institute of Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010201","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009898","name":"Defense Health Agency Consortium","doi-asserted-by":"publisher","award":["W81XWH-19-0210"],"award-info":[{"award-number":["W81XWH-19-0210"]}],"id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.lanmic.2024.101000","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T15:04:00Z","timestamp":1739372640000},"page":"101000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2\u00a0randomised controlled\u00a0study"],"prefix":"10.1016","volume":"6","author":[{"given":"Melinda J","family":"Hamer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin C","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Regules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Mendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D","family":"Sanborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine M","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani L","family":"Liggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Royalty Tredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L","family":"Warfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal W","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bedell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2024.101000_bib1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/517537","article-title":"Outbreak of chikungunya on reunion island: early clinical and laboratory features in 157\u00a0adult patients","volume":"44","author":"Borgherini","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101000_bib2","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cmi.2015.02.024","article-title":"Chikungunya infection: self-reported rheumatic morbidity and impaired quality of life persist 6\u00a0years later","volume":"21","author":"Marimoutou","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.lanmic.2024.101000_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40121-014-0043-9","article-title":"Chikungunya in the Caribbean: an epidemic in the making","volume":"3","author":"Mowatt","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.lanmic.2024.101000_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009055","article-title":"Measuring the global burden of chikungunya and Zika viruses: a systematic review","volume":"15","author":"Puntasecca","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.lanmic.2024.101000_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007563","article-title":"Estimating the cost of illness and burden of disease associated with the 2014\u20132015 chikungunya outbreak in the U.S. Virgin Islands","volume":"13","author":"Feldstein","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.lanmic.2024.101000_bib9","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.4161\/hv.24063","article-title":"Current biodefense vaccine programs and challenges","volume":"9","author":"Wolfe","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanmic.2024.101000_bib10","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1016\/j.vaccine.2012.09.049","article-title":"Immune interference in the setting of same-day administration of two similar inactivated alphavirus vaccines: eastern equine and western equine encephalitis","volume":"30","author":"Reisler","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2024.101000_bib11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/514240","article-title":"Immunologic interference from sequential administration of live attenuated alphavirus vaccines","volume":"177","author":"McClain","year":"1998","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101000_bib12","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1016\/j.vaccine.2009.02.090","article-title":"Immune interference after sequential alphavirus vaccine vaccinations","volume":"27","author":"Pittman","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2024.101000_bib13","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.cell.2019.04.006","article-title":"Cryo-EM structure of chikungunya virus in complex with the Mxra8 receptor","volume":"177","author":"Basore","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.lanmic.2024.101000_bib14","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2024.101000_bib15","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2020.2477","article-title":"Effect of a chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial","volume":"323","author":"Chen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.lanmic.2024.101000_bib16","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminum hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2\u00a0trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101000_bib17","first-page":"119","article-title":"Persistence in humans of antibody after immunization with four alphavirus vaccines","volume":"3","author":"DeMeio","year":"1979","journal-title":"Asian J\u00a0Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101000_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4049\/jimmunol.107.3.643","article-title":"Production and evaluation of a formalin-killed chikungunya vaccine","volume":"107","author":"Harrison","year":"1971","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.lanmic.2024.101000_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijid.2020.03.073","article-title":"Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort","volume":"95","author":"Yoon","year":"2020","journal-title":"Int J\u00a0Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101000_bib20","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/infdis\/jiw431","article-title":"A\u00a0virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all chikungunya virus genotypes","volume":"214","author":"Goo","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.lanmic.2024.101000_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/iai.4.1.37-43.1971","article-title":"Cross-protection in hamsters immunized with group A\u00a0arbovirus vaccines","volume":"4","author":"Cole","year":"1971","journal-title":"Infect Immun"},{"key":"10.1016\/j.lanmic.2024.101000_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1128\/am.26.4.485-488.1973","article-title":"Possible evidence for interference with Venezuelan equine encephalitis virus vaccination of equines by pre-existing antibody to eastern or western equine encephalitis virus, or both","volume":"26","author":"Calisher","year":"1973","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.lanmic.2024.101000_bib23","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/v14071502","article-title":"Efficacy of Western, Eastern, and Venezuelan equine encephalitis (WEVEE) virus-replicon particle (VRP) vaccine against WEEV in a non-human primate animal model","volume":"14","author":"Burke","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.lanmic.2024.101000_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav3113","article-title":"A\u00a0virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates","volume":"11","author":"Ko","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.lanmic.2024.101000_bib25","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.vaccine.2010.01.065","article-title":"Co-administration of viral vector-based vaccines suppresses antigen-specific effector CD8T cells","volume":"28","author":"Yashima","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2024.101000_bib26","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1073\/pnas.81.15.4702","article-title":"An evolutionary tree relating eight alphaviruses, based on amino terminal sequences of their glycoproteins","volume":"81","author":"Bell","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lanmic.2024.101000_bib27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0042-6822(85)90342-3","article-title":"Biochemical and biological characteristics of epitopes on the E1 glycoprotein of western equine encephalitis virus","volume":"142","author":"Hunt","year":"1985","journal-title":"Virology"},{"key":"10.1016\/j.lanmic.2024.101000_bib28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/297070a0","article-title":"Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis","volume":"297","author":"Schmaljohn","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.lanmic.2024.101000_bib29","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1016\/j.cell.2023.05.019","article-title":"Vaccine elicitation and structural basis for antibody protection against alphaviruses","volume":"186","author":"Sutton","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.lanmic.2024.101000_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herve","year":"2019","journal-title":"NPJ Vaccines"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524724002684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524724002684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:50:34Z","timestamp":1762638634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524724002684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666524724002684"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2024.101000","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of an adjuvanted chikungunya virus virus-like particle (CHIKV VLP) vaccine in previous recipients of other alphavirus vaccines versus alphavirus vaccine-naive controls: an open-label, parallel-group, age-matched, sex-matched, phase 2\u00a0randomised controlled\u00a0study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2024.101000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101000"}}